Tagrisso Chemotherapy Combo Achieves Significan...

By João L. Carapinha

July 28, 2025

The FLAURA2 Phase III trial's final analysis confirms that the Tagrisso chemotherapy combo improves overall survival (OS) in untreated patients with EGFR-mutated NSCLC. This combination of osimertinib with pemetrexed and platinum-based chemotherap...
MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Onc...
NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patie...
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study
BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhi...
NICE Approves Transformative Multiple Myeloma Treatment
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
What are the Plans and Implications for Keytruda´s Biosimilar
Blinatumomab Benefit Assessment for ALL and Health Economics
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
Pluvicto Prostate Cancer Trial: Phase III Results
HPV-Related Cancer Trends in South Africa 2011-2021